biotech news today glp-1 The arms race just got a new contender. Structure Therapeutics' oral pill aleniglipron cleared a mid-stage trial with clinically meaningful weight loss and a clean safety profile. Phase 3 is now evaluate the pharmaceuticals and biotechnology
Description
Semaglutide has been shown to improve liver labs, modulate lipid metabolism, and lower hepatic inflammation, with effects that appear at least partly independent of weight loss
That could be caused by pruning of some nerve fibres, or the growth of nerves that are not yet covered with insulating sheaths, though more work is needed to confirm the finding
Most employers are not choosing this path, although in some industries, like biotechnology, it has gained some traction
This partnership ensures results are not left to chance
Nausea occurred at significantly elevated rates across all dose levels compared to placebo
